Do analysts prefer EVGN or CARM?

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts prefer CARM or UPC?

Carisma Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, CARM or UPC?

Universe Pharmaceuticals has higher revenue and earnings than Carisma Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carisma Therapeutics $10.77M 0.03 -$60.48M $0.73 0.01 Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A

Is CARM or UPC more profitable?

Universe Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Universe Pharmaceuticals N/A N/A N/A

Do analysts recommend ITRM or CARM?

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is ITRM or CARM more profitable?

Iterum Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Carisma Therapeutics -254.28% N/A -192.17%

Do analysts recommend JAGX or CARM?

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Jaguar Animal Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Carisma Therapeutics (CARM) Competitors

$0.0081 0.00 (0.00%)

As of 06/26/2026 02:58 PM Eastern

Compare

CARM vs. EVGN, UPC, ITRM, PPBT, and JAGX

Should you buy Carisma Therapeutics stock or one of its competitors? MarketBeat compares Carisma Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carisma Therapeutics include Evogene (EVGN), Universe Pharmaceuticals (UPC), Iterum Therapeutics (ITRM), Purple Biotech (PPBT), and Jaguar Animal Health (JAGX). These companies are all part of the "medical" sector.

How does Carisma Therapeutics compare to Evogene?

Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

10.4% of Evogene shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 7.4% of Evogene shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-158.82%	-80.37%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Evogene has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Evogene had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.29 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media.

Company	Overall Sentiment
Evogene	Neutral
Carisma Therapeutics	Neutral

Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	0.89	-$8.48M	-$1.39	N/A
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01

Summary

Carisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks.

How does Carisma Therapeutics compare to Universe Pharmaceuticals?

Carisma Therapeutics (NASDAQ:CARM) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Carisma Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Universe Pharmaceuticals	N/A	N/A	N/A

Carisma Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Universe Pharmaceuticals has higher revenue and earnings than Carisma Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A

In the previous week, Universe Pharmaceuticals had 5 more articles in the media than Carisma Therapeutics. MarketBeat recorded 5 mentions for Universe Pharmaceuticals and 0 mentions for Carisma Therapeutics. Universe Pharmaceuticals' average media sentiment score of 1.87 beat Carisma Therapeutics' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Universe Pharmaceuticals	Very Positive

Summary

Universe Pharmaceuticals beats Carisma Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Carisma Therapeutics compare to Iterum Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Iterum Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Iterum Therapeutics has higher earnings, but lower revenue than Carisma Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01

In the previous week, Iterum Therapeutics had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Iterum Therapeutics and 0 mentions for Carisma Therapeutics. Iterum Therapeutics' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Carisma Therapeutics	Neutral

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Carisma Therapeutics beats Iterum Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Carisma Therapeutics compare to Purple Biotech?

Carisma Therapeutics (NASDAQ:CARM) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Purple Biotech has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Purple Biotech	N/A	-123.63%	-98.72%

Carisma Therapeutics currently has a consensus target price of $1.00, suggesting a potential upside of 12,245.68%. Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 1,685.71%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Carisma Therapeutics is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Purple Biotech has lower revenue, but higher earnings than Carisma Therapeutics. Purple Biotech is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

In the previous week, Purple Biotech had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for Purple Biotech and 0 mentions for Carisma Therapeutics. Purple Biotech's average media sentiment score of 0.43 beat Carisma Therapeutics' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Purple Biotech	Neutral

Carisma Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Carisma Therapeutics beats Purple Biotech on 10 of the 15 factors compared between the two stocks.

How does Carisma Therapeutics compare to Jaguar Animal Health?

Jaguar Animal Health (NASDAQ:JAGX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Jaguar Animal Health had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Jaguar Animal Health and 0 mentions for Carisma Therapeutics. Jaguar Animal Health's average media sentiment score of 0.63 beat Carisma Therapeutics' score of 0.00 indicating that Jaguar Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Jaguar Animal Health	Positive
Carisma Therapeutics	Neutral

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Jaguar Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

12.0% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 2.0% of Jaguar Animal Health shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jaguar Animal Health has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Jaguar Animal Health has a net margin of -169.04% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Jaguar Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-169.04%	-1,194.94%	-115.55%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Jaguar Animal Health has higher revenue and earnings than Carisma Therapeutics. Jaguar Animal Health is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51M	0.16	-$53.43M	-$591.92	N/A
Carisma Therapeutics	$10.77M	0.03	-$60.48M	$0.73	0.01

Summary

Carisma Therapeutics beats Jaguar Animal Health on 10 of the 17 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARM vs. The Competition

Export

Metric	Carisma Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$339K	$3.01B	$6.70B	$12.22B
Dividend Yield	N/A	1.77%	2.67%	6.13%
P/E Ratio	0.01	19.27	25.76	24.17
Price / Sales	0.03	335.98	559.68	101.60
Price / Cash	N/A	56.66	46.99	54.37
Price / Book	-0.01	4.21	10.77	6.35
Net Income	-$60.48M	$64.45M	$3.57B	$337.63M
7 Day Performance	N/A	2.23%	2.15%	0.06%
1 Month Performance	N/A	1.36%	1.06%	-0.15%
1 Year Performance	N/A	29.73%	34.16%	27.55%

Carisma Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARM Carisma Therapeutics	2.5376 of 5 stars	$0.01 flat	$1.00 +12,245.7%	-98.0%	$339K	$10.77M	0.01	20
EVGN Evogene	0.9956 of 5 stars	$0.49 -1.6%	N/A	-69.3%	$4.35M	$3.85M	N/A	140	Short Interest Increase
UPC Universe Pharmaceuticals	1.0572 of 5 stars	$3.04 +6.7%	N/A	-21.9%	$1.61M	$17.86M	N/A	220	News Coverage Gap Down
ITRM Iterum Therapeutics	0.0382 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10	News Coverage
PPBT Purple Biotech	2.4113 of 5 stars	$1.77 +4.1%	$30.00 +1,594.9%	-92.7%	$1.58M	N/A	N/A	20	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, UPC, ITRM, PPBT, and JAGX

How does Carisma Therapeutics compare to Evogene?

Summary

How does Carisma Therapeutics compare to Universe Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Iterum Therapeutics?

Summary

How does Carisma Therapeutics compare to Purple Biotech?

Summary

How does Carisma Therapeutics compare to Jaguar Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, UPC, ITRM, PPBT, and JAGX

How does Carisma Therapeutics compare to Evogene?

Do insiders & institutionals believe in EVGN or CARM?

Is EVGN or CARM more profitable?

Which has more volatility and risk, EVGN or CARM?

Do analysts prefer EVGN or CARM?

Does the media refer more to EVGN or CARM?

Which has better valuation and earnings, EVGN or CARM?

Summary

How does Carisma Therapeutics compare to Universe Pharmaceuticals?

Do analysts prefer CARM or UPC?

Is CARM or UPC more profitable?

Which has more risk & volatility, CARM or UPC?

Do institutionals and insiders have more ownership in CARM or UPC?

Which has preferable valuation & earnings, CARM or UPC?

Does the media prefer CARM or UPC?

Summary

How does Carisma Therapeutics compare to Iterum Therapeutics?

Do institutionals & insiders have more ownership in ITRM or CARM?

Is ITRM or CARM more profitable?

Which has more volatility and risk, ITRM or CARM?

Which has stronger earnings & valuation, ITRM or CARM?

Does the media prefer ITRM or CARM?

Do analysts recommend ITRM or CARM?

Summary

How does Carisma Therapeutics compare to Purple Biotech?

Is CARM or PPBT more profitable?

Do analysts recommend CARM or PPBT?

Which has preferable earnings and valuation, CARM or PPBT?

Does the media refer more to CARM or PPBT?

Which has more risk & volatility, CARM or PPBT?

Do insiders & institutionals have more ownership in CARM or PPBT?

Summary

How does Carisma Therapeutics compare to Jaguar Animal Health?

Does the media refer more to JAGX or CARM?

Do analysts recommend JAGX or CARM?

Do institutionals and insiders have more ownership in JAGX or CARM?

Which has more risk and volatility, JAGX or CARM?

Is JAGX or CARM more profitable?

Which has stronger valuation and earnings, JAGX or CARM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools